Internship

Intern – BI Analyst

Posted on 4/15/2025

American Cancer Society

American Cancer Society

5,001-10,000 employees

Advocacy, research, and patient support for cancer

Compensation Overview

$15/hr

Atlanta, GA, USA

Candidates from all US geographies will be considered for this remote internship.

Category
Data Management
Data Engineering
Data & Analytics
Required Skills
SQL
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a American Cancer Society referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Possess strong knowledge of MS Office Suite, including Word, SharePoint, PowerPoint, and Excel report and dashboard creation.
  • Experience working with Excel data functions such as Vlookup or Pivot Tables.
  • Experience using SQL a plus.
  • Must be available for entirety of 8-week program: June 2 – July 25, 2025, at 37.5 hours per week.
  • Full-time student, if you are an undergraduate student, you have completed your freshman year of college.
  • Have a minimum of a B average (cumulative 3.0 on 4.0 scale);
  • Plan to continue your education in the following term/semester;
  • Upload a resume upon application submission.
Responsibilities
  • Assist in developing and implementing standards for IT documentation.
  • Organize and maintain a centralized repository for IT-related documents.
  • Collaborate with IT teams to ensure documentation is accurate, consistent, and up to date.
  • Conduct regular audits to identify outdated or incomplete documentation.
  • Develop and maintain templates for different types of IT documents.
  • Provide recommendations for streamlining documentation processes and workflows.
  • Support the review and approval process for new or updated documentation.
Desired Qualifications
  • Experience using SQL a plus.
American Cancer Society

American Cancer Society

View

The American Cancer Society focuses on fighting cancer through various means, including advocacy, research, and patient support. Their efforts aim to improve the lives of individuals affected by cancer and their families by providing resources and assistance for prevention, detection, treatment, and survivorship. Unlike other organizations, the American Cancer Society uniquely combines these elements to create a comprehensive approach to cancer care. Their goal is to end cancer as we know it, ensuring that everyone has access to the necessary tools and support to combat this disease.

Company Size

5,001-10,000

Company Stage

Series B

Total Funding

$2.7M

Headquarters

Atlanta, Georgia

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI-driven research collaborations enhance cancer treatment options.
  • Emerging technologies like TAR-200 offer new cancer treatment methods.
  • Expansion of diagnostic access in underserved areas improves early cancer detection.

What critics are saying

  • Emerging technologies may reduce demand for traditional cancer support services.
  • Advanced diagnostics access may shift focus from Society's regional initiatives.
  • AI collaborations could outpace traditional research funding methods.

What makes American Cancer Society unique

  • American Cancer Society funds diverse cancer research projects across multiple universities.
  • It engages communities through events like Relay For Life to raise awareness.
  • The Society partners with businesses to support cancer research and patient services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

401(k) Retirement Plan

Wellness Program

Professional Development Budget

Company News

PharmiWeb
Apr 24th, 2025
Hutchmed Highlights Data To Be Presented At Aacr Annual Meeting 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

PR Newswire
Apr 23rd, 2025
Center For Better Aging Extends Chicago Testing, Diagnostic Access

St. Bernard Hospital CT/Mammography Suite Addresses South Side's Health RisksCHICAGO, April 23, 2025 /PRNewswire/ -- The Center for Better Aging has completed its first capital investment, bringing much-needed access to advanced health screening and diagnostic resources to South Side residents. A next-generation CT and mammography suite will provide heart scans and early breast cancer detection

PR Newswire
Apr 21st, 2025
Johnson Johnson Unveils Highly Anticipated And Potential Practice-Changing Data In Bladder Cancer Treatment At Aua

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancerRARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology plenary session on Saturday, April 26.Bladder cancer ranks among the top ten most common cancers worldwide, affecting nearly a million people each year.1 Despite advancements, standard treatment has remained largely unchanged for over 40 years, leaving patients with limited treatment options if initial BCG therapy does not work.2 TAR-200 delivers sustained medication directly into the bladder and, in a pre-clinical setting, has been shown to allow for depth of penetration across bladder tissue layers.3"Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially for those with HR-NMIBC, a highly recurrent disease that often necessitates difficult, life-altering decisions like bladder removal," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. "TAR-200 provides a new approach, with clinical data showing an impressive complete response rate, meaning the cancer was undetectable following treatment. The highly anticipated 12-month duration of response findings from our Cohort 2, SunRISe-1 study further support the potential for patients to remain cancer-free for a clinically meaningful period."A second plenary presentation will feature first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy in patients with BCG–unresponsive, papillary-only HR-NMIBC. In this patient population, bladder removal remains a standard treatment, but many patients are elderly, have significant comorbidities, or are unwilling to undergo radical surgery, making treatment challenging.4"Patients deserve more than the currently available treatment options

PR Newswire
Apr 17th, 2025
Nference And Beigene Collaborate To Drive New B-Cell Cancer Research

Real-world data study aims to improve treatment options for chronic lymphocytic leukemia and small lymphocytic lymphoma patientsCAMBRIDGE, Mass., April 17, 2025 /PRNewswire/ -- nference, a company dedicated to transforming healthcare by making biomedical data computable, today announced a collaboration with BeiGene, Ltd, a global oncology company that intends to change its name to BeOne Medicines Ltd., to unlock new insights in treating B-cell cancers. The collaboration will leverage nference's proprietary Agentic AI platform to deepen understanding of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) treatment patterns. B-cell cancers, including CLL and SLL, are a group of malignancies affecting lymphocytes, a type of white blood cell crucial to immune function. These cancers impact thousands, with CLL being the most common adult leukemia in the U.S. This retrospective descriptive analysis will review more than 700 patient charts to identify real-world treatment patterns

MSU Today
Apr 14th, 2025
American Cancer Society grant fuels MSU research in colorectal, breast and cervical cancer

Four dedicated researchers from Michigan State University have received grants totaling more than $3 million from the American Cancer Society, or ACS, to find new ways to prevent, detect, treat and help patients survive colorectal, breast and cervical cancer.

INACTIVE